-
11.发明授权公开(公告)号：US10208024B2
公开(公告)日：2019-02-19
申请号：US15333148
申请日：2016-10-24
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , James F. Blake , Adam Cook , Indrani W. Gunawardana , Kevin W. Hunt , Andrew T. Metcalf , David Moreno , Li Ren , Tony P. Tang
IPC: C07D403/14 , C07D401/14 , C07D413/14 , A61K31/501 , A61K31/5377 , C12Q1/68 , A61K45/06 , C12Q1/6886 , G01N33/574
Abstract: Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.
-
![SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS](/abs-image/US/2018/05/17/US20180133207A1/abs.jpg.150x150.jpg)
公开(公告)号：US20180133207A1
公开(公告)日：2018-05-17
申请号：US15860894
申请日：2018-01-03
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , James Collier , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Ginelle A. Ramann , Tony P. Tang , Li Ren , Shane M. Walls
IPC: A61K31/4545 , A61K45/06 , A61P35/00 , A61P35/02 , A61K31/444 , A61K31/506 , A61K31/501 , A61K31/497 , A61K31/5377
CPC classification number: A61K31/4545 , A61K31/4162 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P1/00 , A61P1/12 , A61P35/00 , A61P35/02 , C07D471/04
Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
![Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors](/abs-image/US/2018/12/04/US10144734B2/abs.jpg.150x150.jpg)
公开(公告)号：US10144734B2
公开(公告)日：2018-12-04
申请号：US15858929
申请日：2017-12-29
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , James Collier , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Ginelle A. Ramann , Tony P. Tang , Li Ren , Shane M. Walls
IPC: C07D471/04 , A61K31/4162 , A61P1/00 , A61P35/00
Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
![Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors](/abs-image/US/2018/11/27/US10137124B2/abs.jpg.150x150.jpg)
公开(公告)号：US10137124B2
公开(公告)日：2018-11-27
申请号：US15860852
申请日：2018-01-03
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Tony P. Tang , Li Ren
IPC: A61K31/437 , A61K31/496 , C07D471/04 , A61P1/12 , A61P35/04 , C07D519/00 , A61P35/02 , A61P35/00 , A61K31/444 , A61K31/4985 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K45/06 , A61K31/551
Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
![SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS](/abs-image/US/2018/05/17/US20180133200A1/abs.jpg.150x150.jpg)
公开(公告)号：US20180133200A1
公开(公告)日：2018-05-17
申请号：US15860852
申请日：2018-01-03
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Tony P. Tang , Li Ren
IPC: A61K31/444 , A61K31/496 , A61P35/00 , A61P35/02 , A61K45/06 , A61K31/5377 , A61K31/4985 , A61K31/506 , A61K31/551
CPC classification number: C07D471/04 , A61K31/444 , A61K31/496 , A61K31/4985 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K31/551 , A61K45/06 , A61P1/12 , A61P35/00 , A61P35/02 , A61P35/04 , C07D519/00
Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
Patent Agency Ranking
公开(公告)号：US09556139B2
公开(公告)日：2017-01-31
申请号：US14702947
申请日：2015-05-04
Applicant: Array BioPharma Inc.
Inventor： Laurence E. Burgess , Christopher T. Clark , Adam Cook , Christopher P. Corrette , Robert Kirk DeLisle , George A. Doherty , Kevin W. Hunt , Todd T. Romoff , Ganghyeok Kim
IPC: A61K31/352 , C07D311/58 , C07D405/12 , C07D407/12
CPC classification number: C07D311/58 , C07D311/04 , C07D405/12 , C07D407/12
Abstract: Provided herein are compounds of Formula I: in which A1, A2, W, L, G, R7a, R7b, R8, R9 and R10 have the meanings given in the specification, which are DP2 receptor modulators useful in the treatment of immunologic diseases.
Abstract translation: 式（Ⅳ，Ⅵ）化合物：其中A1，A2，P2，P3，R7a，R7b，R8，R9，R10和Z2具有说明书中给出的含义，是可用于制备DP2受体调节剂的化合物 免疫疾病的治疗。
-
17.发明申请公开(公告)号：US20190300511A1
公开(公告)日：2019-10-03
申请号：US16276326
申请日：2019-02-14
Applicant: Array BioPharma Inc.
Inventor： Steven W. Andrews , James F. Blake , Adam Cook , Indrani W. Gunawardana , Kevin W. Hunt , Andrew T. Metcalf , David Moreno , Li Ren , Tony P. Tang
IPC: C07D403/14 , C07D413/14 , C07D401/14 , G01N33/574 , A61K31/501 , A61K45/06 , A61K31/5377 , C12Q1/6886
Abstract: Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.
-
![Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors](/abs-image/US/2019/01/08/US10172851B2/abs.jpg.150x150.jpg)
公开(公告)号：US10172851B2
公开(公告)日：2019-01-08
申请号：US15860808
申请日：2018-01-03
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Tony P. Tang , Li Ren
IPC: C07D401/02 , C07D401/10 , A61K31/437 , A61K31/4353 , A61K31/496 , C07D471/04 , A61P1/12 , A61P35/04 , C07D519/00 , A61P35/02 , A61P35/00 , A61K31/444 , A61K31/4985 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K45/06 , A61K31/551
Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
![Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors](/abs-image/US/2019/01/08/US10172845B2/abs.jpg.150x150.jpg)
公开(公告)号：US10172845B2
公开(公告)日：2019-01-08
申请号：US15861244
申请日：2018-01-03
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , James Collier , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Ginelle A. Ramann , Tony P. Tang , Li Ren , Shane M. Walls
IPC: A61K31/437 , A61K31/4353 , A61K31/4545 , A61K31/4162 , C07D471/04 , A61P1/00 , A61P35/00 , A61P35/02 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P1/12
Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
![Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors](/abs-image/US/2018/10/30/US10112942B2/abs.jpg.150x150.jpg)
公开(公告)号：US10112942B2
公开(公告)日：2018-10-30
申请号：US15858240
申请日：2017-12-29
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Tony P. Tang , Li Ren
IPC: C07D401/02 , C07D401/10 , A61K31/437 , A61K31/4353 , C07D471/04 , A61P1/12 , A61P35/04 , C07D519/00
Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
-
-
-
-
-
-
-
-
Search Results
47
records
(took 0.071 seconds)
